NorthStar Nuclear Therapies

NorthStar Nuclear Therapies is a subsidiary of NorthStar Medical Technologies, LLC, dedicated to the development and commercialization of therapeutic radiopharmaceuticals and radioisotopes. The company specializes in Targeted Alpha Therapy (TAT) and Targeted Beta Therapy, utilizing proprietary, non-reactor-based production methods to supply high-purity isotopes such as Actinium-225 (Ac-225) and Copper-67 (Cu-67). NorthStar Nuclear Therapies collaborates with biotechnology and pharmaceutical partners to integrate these isotopes into novel therapeutic candidates for oncology, infectious diseases, and inflammatory conditions. By providing a reliable, commercial-scale supply of therapeutic radionuclides, the company addresses critical supply chain constraints and supports the advancement of next-generation cancer treatments.